ABPO

0.900028.77%
RL

Ronald Levy

Member of Scientific Advisory Board

Dr. Ronald Levy, M.D., Ph.D., also known as Ron, is Co-Founder of TwoStep Therapeutics, Inc. Dr. Levy is Advisor of Trio Pharmaceuticals Inc. Dr. Levy serves as Member of Medical Advisory Board at Nurix Therapeutics, Inc. since 2023. He is Member of Scientific Advisory Board of Khloris Biosciences, Inc. He serves as Scientific Advisory Board Member at Kira Pharmaceuticals. He is Member of the Scientific Advisory Board at BeiGene Ltd. since April 2021. Dr. Ronald Levy serves as Member of Scientific Advisory Board at Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since June 2023. He serves as Member of Immuno-Oncology Scientific Advisory Board at BioLineRx Ltd. since December 2021. He was a Member of Scientific Advisory Board at Sunesis Pharmaceuticals, Inc. (formerly known as Viracta Therapeutics, Inc.) since September 2018 until February 2025. He serves as Member of Scientific Advisory Board at Quadriga BioSciences, Inc. He serves as Member of Advisory Board at Abintus Bio Inc. Dr. Levy is a Member of Scientific Advisory Board at Forty Seven, Inc. since October 03, 2018. Dr. Levy served as Special Advisor at Kite Pharma, Inc. Dr. Levy serves as a Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. His research is focused on the study of lymphomas and tumors of the immune system. He has helped to develop and test the first antibody against cancer that was approved by the US Food and Drug Administration (FDA) for the treatment of lymphomas. Dr. Levy served as the Chief of the Division of Oncology at Stanford University. Dr. Levy serves as Member of Scientific Advisory Board at Abpro Holdings, Inc. (formerly known as Abpro Corporation). Dr. Levy serves as a Member of Scientific Advisory Board at Five Prime Therapeutics, Inc. He serves as a Director of American Association For Cancer Research. He served as a Member of the Scientific Advisory Board at Innate Pharma S.A. since 2013. He serves as a Member of Scientific Advisory Board at InNexus Biotechnology, Inc. and ImmunoCellular Therapeutics, Ltd. He serves as a Member of Scientific Advisory Board of Sequenta, Inc. He served as a Member of Scientific Advisory Board at Dragonfly Therapeutics, Inc until June 2025. He has been Member of Scientific Advisory Board at Immune Design Corp. since September 21, 2016. He served as a Member of Scientific Advisory Board at BeiGene, Ltd. He served as a Member of Medical Advisory Board at Cell Genesys, Inc. He served as a Member of Scientific Advisory Board at Kite Pharma, Inc. He serves as Advisor of Mahana Therapeutics, Inc. Dr. Levy served as a Member of Oncology Board of Advisors at Checkmate Pharmaceuticals, Inc. until 2021. Dr. Levy served as a Member of the Advisory Board at Symphogen A/S since July 2005. He served as a Member of Scientific Advisory Board for BiTE Antibody Technology at Micromet, Inc., since March 2008. He served as a Member of Scientific Advisory Board at XTL Biopharmaceuticals Ltd. He served as a Member of Scientific Advisory Board of Xcyte Therapies Inc. Dr. Levy research has focused for many years on monoclonal antibodies to B cells. His landmark research on the basic immuno-biology of lymphocytes and on monoclonal antibodies led to the development of rituximab, a widely successful treatment for B-cell lymphoma. He is conducting clinical trials of a lymphoma vaccine. His research concentrates on the study of malignant lymphoma, using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Dr. Levy has received international acclaim for his work using the body's own arsenal to fight cancer. In 1982, he shared the first Armand Hammer Award for Cancer Research and was later awarded the Ciba-Geigy/Drew Award in Biomedical Research, the American Society of Clinical Oncology Karnofsky Award, the General Motors Charles Kettering Prize, the Key to the Cure Award by the Cure for Lymphoma Foundation. Dr. Levy is using lymphocyte receptors as targets for new therapies for lymphoma. Dr. Levy has received numerous honors and awards, including the Damashek Prize from the American Society of Hematology in 2004, the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in 2003, the Evelyn Hoffman Memorial Award from the Lymphoma Research Foundation of America in 2001 and the Medal of Honor from the American Cancer Society in 2000. In 2009, he won the King Faisal International Prize. Dr. Levy has published over 270 articles in the fields of oncology and immunology. He is an elected Member of the National Academy of Sciences in 2008 and the Institute of Medicine. Dr. Levy received his B.A. in Biochemistry from Harvard University in 1963 and his Medical Degree from Stanford University in 1968.

Positions